Novartis Ups the Ante, Snags Remaining Stake in Chiron

Drug Industry Daily
KEYWORDS Deals / FDA
A A

After being spurned by Chiron six weeks ago, Novartis has agreed to pay $5.1 billion to acquire full control of the California-based drugmaker -- a move that significantly boosts its presence in the red-hot vaccines market.

To View This Article:

Login

Subscribe To Drug Industry Daily